NASOPORE
Commercial- Indications
- ENT surgery
Company intelligence / Profile preview
Polyganics developed a range of CE-marked/FDA-cleared bioresorbable medical devices based on proprietary synthetic polymers. Its marketed products addressed soft tissue reconstruction—including peripheral nerve repair—and ENT/gastrointestinal surgeries. The company’s Dura Sealant Patch program received significant grant funding to complete clinical development by the late 2010s. As of its October 2022 acquisition by Collagen Matrix, Polyganics had multiple commercial product lines and an active R&D pipeline focused on next-generation regenerative devices.
6 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Polyganics.